Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 2/20 | 0.49 |
| ▸ | PELI1 | Q96FA3 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TOP1 | P11387 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16586874 | 0.90 | ALOX5 (0.43) | TDP2PELI1MAPTALDH1A1RAB9A | |
| SCHEMBL18605359 | 0.85 | MAPT (0.52) | TDP2PELI1MAPTALDH1A1NPC1 | |
| SCHEMBL7930381 | 0.83 | ERN1 (0.56) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7838339 | 0.83 | LMNA (0.64) | TDP2MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL2009026 | 0.81 | TSHR (0.67) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29526232 | 0.81 | TSHR (0.67) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18094675 | 0.81 | TRPM2 (0.48) | TDP2PELI1MAPTALDH1A1NFE2L2 | |
| Formic Acid SCHEMBL27530611 | 0.80 | ALDH1A1 (0.55) | PELI1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL30525133 | 0.79 | ERN1 (0.69) | PELI1MAPTALDH1A1NPC1LMNA | |
| SCHEMBL30469335 | 0.79 | TSHR (0.64) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3046902-B1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2018-08-08 | — | — | EP | disclosed |
| US-9630935-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2017-04-25 | — | — | US | disclosed |
| US-20160280671-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2016-09-29 | — | — | US | disclosed |
| CN-105683153-A | Compositions for the treatment of hypertension and/or fibrosis | 维克图斯生物系统有限公司 | 2016-06-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280671-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | TGFB1, REN, TGFB2 | TDP2 4173/4885PELI1 4794/4885MAPT 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.